trending Market Intelligence /marketintelligence/en/news-insights/trending/fHPraOFIWzASLy7kSOsGog2 content esgSubNav
In This List

FDA grants breakthrough therapy designation to Tonix's PTSD drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


FDA grants breakthrough therapy designation to Tonix's PTSD drug

The U.S. FDA granted a breakthrough therapy designation to Tonix Pharmaceuticals Holding Corp.'s TNX-102 SL to treat posttraumatic stress disorder, or PTSD.

The company plans to start enrolling patients in a phase 3 study of the drug in the first quarter of 2017 after receiving FDA agreement on the study design and interim analysis plan.

TNX-102 SL is an investigational new drug and has not been approved for any indication.